Email ID
Password
Scrip   
Amgen posts 24% profit growth despite Aranesp drag
22 October 2009
Christopher Spillane

Amgen's profits crept up as lower costs and taxes helped contain a double-digit decline of sales of its anaemia drug Aranesp (darbepoetin alfa). Third-quarter earnings rose by 24% to $1.4 billion and the company confirmed that full-year revenues will be towards the top end of its forecast.

The...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36